SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 48.91 |
| Enterprise Value ($M) | 52.80 |
| Book Value ($M) | -8.85 |
| Book Value / Share | -2.06 |
| Price / Book | -5.52 |
| NCAV ($M) | -35.30 |
| NCAV / Share | -8.23 |
| Price / NCAV | -1.39 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | n/a |
| Return on Assets (ROA) | -0.03 |
| Return on Equity (ROE) | n/a |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.07 |
| Current Ratio | 0.07 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 1.67 |
| Assets | 28.12 |
| Liabilities | 36.97 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | -1.81 |
| Net Income | -0.75 |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -1.93 |
| Cash from Investing | 36.86 |
| Cash from Financing | -34.89 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Calamos Investment Trust/il | 11.60 | -0.72 | |
| 13G/A | Walleye Capital LLC | 5.44 | -27.17 | |
| 13G/A | Polar Asset Management Partners Inc. | 0.00 | -100.00 | |
| 13G/A | Aqr Capital Management Llc | 0.00 | -100.00 | |
| 13G/A | Cowen And Company, Llc | 4.10 | -67.65 | |
| 13G | Hudson Bay Capital Management LP | 6.77 | ||
| 13G/A | Karpus Management, Inc. | 2.34 | -82.72 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Similar Companies | |
|---|---|
| FFNTF – 4Front Ventures Corp. | FNCH – Finch Therapeutics Group, Inc. |
| FPMI – FluoroPharma Medical, Inc. | GBIM – GlobeImmune, Inc. |
| GCAN – The Greater Cannabis Company, Inc. |
Financial data and stock pages provided by
Fintel.io